Cover Image
市場調查報告書

血友病治療藥市場(組替換凝血因子濃縮製劑,血漿原來凝血因子濃縮製劑,去氨加壓素,抗線維本源溶解劑) - 全球產業分析,規模,構成比,成長率,趨勢及預測

Hemophilia Treatment Drugs Market (Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrates, Desmopressin, and Antifibrinolytic Agents) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2024

出版商 Transparency Market Research 商品編碼 428071
出版日期 內容資訊 英文 188 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
血友病治療藥市場(組替換凝血因子濃縮製劑,血漿原來凝血因子濃縮製劑,去氨加壓素,抗線維本源溶解劑) - 全球產業分析,規模,構成比,成長率,趨勢及預測 Hemophilia Treatment Drugs Market (Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrates, Desmopressin, and Antifibrinolytic Agents) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2024
出版日期: 2018年04月03日 內容資訊: 英文 188 Pages
簡介

本報告以血友病治療藥的全球市場為焦點,提供今後變化依各產品類型、適應症、銷路,及地區等各分類的預測,產業結構,推動、阻礙因素,機會,競爭環境等分析資訊及主要企業簡介彙整。

第1章 序

  • 市場定義和範圍
  • 市場區隔
  • 主要調查目的
  • 調查亮點

第2章 前提和調查方法

第3章 摘要整理 - 血友病治療藥的全球市場

第4章 市場概要

  • 簡介
    • 產品類型定義
    • 產業發展史
  • 概要
  • 重要市場指標
    • 各地區、國家
    • 產品、用途、各銷路
    • 各目標市場 - 全球的情形
  • 市場動態
    • 推動要素
    • 阻礙因素
    • 機會
  • 血友病治療藥全球市場的分析與預測
    • 市場收益預測(單位:100萬美元)
  • 血友病治療藥市場 - 全球的供需情形
  • 波特的五力分析
  • 價值鏈分析
  • 市場展望

第5章 血友病治療藥全球市場的分析與預測 - 各產品類型

  • 簡介和定義
  • 重要發現、發展
  • 重要趨勢
  • 市場金額預測 - 各產品類型
    • 組替換凝血因子濃縮製劑
    • 血漿原來凝血因子濃縮製劑
    • 去氨加壓素
    • 抗線維本源溶解劑
  • 產品類型比較矩陣
  • 市場向心力 - 各產品類型

第6章 血友病治療藥全球市場的分析與預測 - 各適應症

  • 簡介和定義
  • 重要發現、發展
  • 重要趨勢
  • 市場金額預測 - 各適應症
    • A型血友病
    • B型血友病
    • 其他
  • 適應症比較矩陣
  • 市場向心力 - 各適應症

第7章 血友病治療藥全球市場的分析與預測 - 各銷路

  • 簡介和定義
  • 重要發現、發展
  • 重要趨勢
  • 市場金額預測 - 各銷路
    • 院內藥局
    • 醫藥品零售店
    • 電子商務
  • 各銷路比較矩陣
  • 市場向心力 - 各銷路

第8章 血友病治療藥全球市場的分析與預測 - 各地區

  • 重要發現
  • 政策和法規
  • 市場金額預測 - 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中南美
    • 中東、非洲
  • 市場向心力 - 各地區、國家

第9章 北美血友病治療藥市場分析與預測

  • 簡介
    • 重要發現
  • 市場金額預測 - 各產品類型
    • 組替換凝血因子濃縮製劑
    • 血漿原來凝血因子濃縮製劑
    • 去氨加壓素
    • 抗線維本源溶解劑
  • 市場金額預測 - 各適應症
    • A型血友病
    • B型血友病
    • 其他
  • 市場金額預測 - 各銷路
    • 院內藥局
    • 醫藥品零售店
    • 電子商務
  • 市場金額預測 - 各國
    • 美國
    • 加拿大
  • 市場向心力分析
    • 各產品類型
    • 各適應症
    • 各銷路
    • 各國

第10章 歐洲血友病治療藥市場分析與預測

第11章 亞太地區血友病治療藥市場分析與預測

第12章 中南美血友病治療藥市場分析與預測

第13章 中東、非洲血友病治療藥市場分析與預測

第14章 競爭環境

  • 市場參與企業 - 競爭矩陣(企業階層、各規模)
  • 市場佔有率分析 - 各企業
  • 企業簡介

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Global Hemophilia Treatment Drugs Market: Overview

Hemophilia is a rare blood disorder. Hemophilia is a combination of two Greek words that is haima (blood) and philia (affection). Hemophilia is a hereditary disorder, passed from parents to the child. Hemophilia is a bleeding disorder which causes excess bleeding and poor blood clotting. The people with hemophilia are generally known as hemophiliacs. There are two main type of hemophilia, hemophilia A and hemophilia B. Hemophilia A or classical hemophilia is the most common type of hemophilia, caused by lack of factor VIII in blood. Hemophilia B also known as Christmas disease, as it was firstly diagnosed in person named Steven Christmas. Hemophilia B is caused by lack of factor IX in blood. Other hemophilia are hemophilia C, Acquired Hemophilia etc. Hemophilia A & B is passed from mother to child, but hemophilia C is passed from both mother and father to child. This report analyzes the current and future prospects of the hemophilia treatment drugs market based on type of product, disease indication, distribution channel and geography.

Global Hemophilia Treatment Drugs Market: Research Methodology

The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of the major radiography techniques in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, analyst presentation and various international and national databases. The report provides estimated market size in terms of US$ Mn for each Product type, disease indication, distribution channel, and geography for the period 2017 to 2024, considering the macro and micro environmental factors. The revenue generated from each product was calculated by considering number of products used in the procedures and their market demand as per their use, number of product launched, average cost of products of each sub segment, trends in industry, end user trend, and adoption rate across all the geographies. The revenue generated for disease indication was calculated on the basis of prevalence of diseases in humans.

Global Hemophilia Treatment Drugs Market: Scope

The market report comprises an elaborated executive summary, which includes market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on type of product, disease indication, distribution channel and geography. The market overview section of the report analyzes market dynamics such as drivers, restraints and opportunities that influence the hemophilia treatment drugs market in the current and future scenario. The report also provides value chain analysis of the market that describes the sequence of activities involved from manufacturing to their final reach to the end users.

Global Hemophilia Treatment Drugs Market: Regional Outlook

Market share analysis among the market players is analyzed to signify percentage share of the major players operating in the market. All these factors will help the market players to decide about the business strategies and plans to strengthen their positions in the global market. Based on geography, the market has been analyzed for countries of North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Market Taxonomy

Global Hemophilia Treatment Drugs Market Revenue, by Product type

Recombinant coagulation factor concentrates

Factor VIII

Factor IX

Combination

Plasma derived coagulation factor concentrates

Factor VIII

Factor IX

Combination

Desmopressin

Antifibrinolytic agents

Global Hemophilia Treatment Drugs Market Revenue, by Disease Indication

Hemophilia A

Hemophilia B

Others

Global Hemophilia Treatment Drugs Market Revenue, by Distribution Channel

Hospital Pharmacies

Retail Pharmacies

E-commerce

Global Hemophilia Treatment Drugs Market Revenue, by Geography

North America

Europe

Asia Pacific

Latin America

Middle East and Africa

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Hemophilia Treatment Drug Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Type Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Key Market Indicators
    • 4.3.1. Region/Country Specific
    • 4.3.2. Product/Application/By Distribution Channel Specific
    • 4.3.3. Target Market Specific - Global Scenario
  • 4.4. Market Dynamics
    • 4.4.1. Drivers
    • 4.4.2. Restraints
    • 4.4.3. Opportunity
  • 4.5. Global Hemophilia Treatment Drug Market Analysis and Forecasts, 2014-2024
    • 4.5.1. Market Revenue Projections (US$ Mn)
  • 4.6. Hemophilia Treatment Drug Market - Global Supply Demand Scenario
  • 4.7. Porter's Five Force Analysis
  • 4.8. Value Chain Analysis
  • 4.9. Market Outlook

5. Global Hemophilia Treatment Drug Market Analysis and Forecasts, By Product Type

  • 5.1. Introduction & Definition
  • 5.2. Key Findings / Developments
  • 5.3. Key Trends
  • 5.4. Market Value Forecast By Product Type, 2014-2024
    • 5.4.1. Recombinant coagulation factor concentrates
      • 5.4.1.1. Factor VIII
      • 5.4.1.2. Factor IX
      • 5.4.1.3. Combination
    • 5.4.2. Plasma derived coagulation factor concentrates
      • 5.4.2.1. Factor VIII
      • 5.4.2.2. Factor IX
      • 5.4.2.3. Combination
    • 5.4.3. Desmopressin
    • 5.4.4. Antifibrinolytic agents
  • 5.5. Product Type Comparison Matrix
  • 5.6. Market Attractiveness By Product Type

6. Global Hemophilia Treatment Drug Market Analysis and Forecasts, By Disease Indication

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Key Trends
  • 6.4. Market Value Forecast By Disease Indication, 2014-2024
    • 6.4.1. Hemophilia A
    • 6.4.2. Hemophilia B
    • 6.4.3. Others
  • 6.5. Disease Indication Comparison Matrix
  • 6.6. Market Attractiveness By Disease Indication

7. Global Hemophilia Treatment Drug Market Analysis and Forecasts, By Distribution

Channel

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Key Trends
  • 7.4. Market Value Forecast By Distribution Channel, 2014-2024
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Retail Pharmacies
    • 7.4.3. E- commerce
  • 7.5. By Distribution Channel Comparison Matrix
  • 7.6. Market Attractiveness By Distribution Channel

8. Global Hemophilia Treatment Drug Market Analysis and Forecasts, By Region

  • 8.1. Key Findings
  • 8.2. Policies and Regulations
  • 8.3. Market Value Forecast By Region
    • 8.3.1. North America
    • 8.3.2. Europe
    • 8.3.3. Asia Pacific
    • 8.3.4. Latin America
    • 8.3.5. Middle East & Africa
  • 8.4. Market Attractiveness By Country/Region

9. North America Hemophilia Treatment Drug Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast By Product Type, 2014-2024
    • 9.2.1. Recombinant coagulation factor concentrates
      • 9.2.1.1. Factor VIII
      • 9.2.1.2. Factor IX
      • 9.2.1.3. Combination
    • 9.2.2. Plasma derived coagulation factor concentrates
      • 9.2.2.1. Factor VIII
      • 9.2.2.2. Factor IX
      • 9.2.2.3. Combination
    • 9.2.3. Desmopressin
    • 9.2.4. Antifibrinolytic agents
  • 9.3. Market Value Forecast By Disease Indication, 2014-2024
    • 9.3.1. Hemophilia A
    • 9.3.2. Hemophilia B
    • 9.3.3. Others
  • 9.4. Market Value Forecast By Distribution Channel, 2014-2024
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail Pharmacies
    • 9.4.3. E- commerce
  • 9.5. Market Value Forecast By Country, 2014-2024
    • 9.5.1. U.S.
    • 9.5.2. Canada
  • 9.6. Market Attractiveness Analysis
    • 9.6.1. By Product Type
    • 9.6.2. By Disease Indication
    • 9.6.3. By Distribution Channel
    • 9.6.4. By Country

10. Europe Hemophilia Treatment Drug Market Analysis and Forecast

  • 10.1.Introduction
    • 10.1.1. Key Findings
  • 10.2.Market Value Forecast By Product Type, 2014-2024
    • 10.2.1. Recombinant coagulation factor concentrates
      • 10.2.1.1. Factor VIII
      • 10.2.1.2. Factor IX
      • 10.2.1.3. Combination
    • 10.2.2. Plasma derived coagulation factor concentrates
      • 10.2.2.1. Factor VIII
      • 10.2.2.2. Factor IX
      • 10.2.2.3. Combination
    • 10.2.3. Desmopressin
    • 10.2.4. Antifibrinolytic agents
  • 10.3.Market Value Forecast By Disease Indication, 2014-2024
    • 10.3.1. Hemophilia A
    • 10.3.2. Hemophilia B
    • 10.3.3. Others
  • 10.4.Market Value Forecast By Distribution Channel, 2014-2024
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. E- commerce
  • 10.5.Market Value Forecast By Country, 2014-2024
    • 10.5.1. Germany
    • 10.5.2. U.K.
    • 10.5.3. France
    • 10.5.4. Spain
    • 10.5.5. Italy
    • 10.5.6. Rest of Europe
  • 10.6.Market Attractiveness Analysis
    • 10.6.1. By Product Type
    • 10.6.2. By Disease Indication
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Asia Pacific Hemophilia Treatment Drug Market Analysis and Forecast

  • 11.1.Introduction
    • 11.1.1. Key Findings
  • 11.2.Market Value Forecast By Product Type, 2014-2024
    • 11.2.1. Recombinant coagulation factor concentrates
      • 11.2.1.1. Factor VIII
      • 11.2.1.2. Factor IX
      • 11.2.1.3. Combination
    • 11.2.2. Plasma derived coagulation factor concentrates
      • 11.2.2.1. Factor VIII
      • 11.2.2.2. Factor IX
      • 11.2.2.3. Combination
    • 11.2.3. Desmopressin
    • 11.2.4. Antifibrinolytic agents
  • 11.3.Market Value Forecast By Disease Indication, 2014-2024
    • 11.3.1. Hemophilia A
    • 11.3.2. Hemophilia B
    • 11.3.3. Others
  • 11.4.Market Value Forecast By Distribution Channel, 2014-2024
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. E- commerce
  • 11.5.Market Value Forecast By Country, 2014-2024
    • 11.5.1. Japan
    • 11.5.2. China
    • 11.5.3. Australia
    • 11.5.4. New Zealand
    • 11.5.5. India
    • 11.5.6. Rest of Asia Pacific
  • 11.6.Market Attractiveness Analysis
    • 11.6.1. By Product Type
    • 11.6.2. By Disease Indication
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country

12. Latin America Hemophilia Treatment Drug Market Analysis and Forecast

  • 12.1.Introduction
    • 12.1.1. Key Findings
  • 12.2.Market Value Forecast By Product Type, 2014-2024
    • 12.2.1. Recombinant coagulation factor concentrates
      • 12.2.1.1. Factor VIII
      • 12.2.1.2. Factor IX
      • 12.2.1.3. Combination
    • 12.2.2. Plasma derived coagulation factor concentrates
      • 12.2.2.1. Factor VIII
      • 12.2.2.2. Factor IX
      • 12.2.2.3. Combination
    • 12.2.3. Desmopressin
    • 12.2.4. Antifibrinolytic agents
  • 12.3.Market Value Forecast By Disease Indication, 2014-2024
    • 12.3.1. Hemophilia A
    • 12.3.2. Hemophilia B
    • 12.3.3. Others
  • 12.4.Market Value Forecast By Distribution Channel, 2014-2024
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. E- commerce
  • 12.5.Market Value Forecast By Country, 2014-2024
    • 12.5.1. Brazil
    • 12.5.2. Mexico
    • 12.5.3. Rest of Latin America
  • 12.6.Market Attractiveness Analysis
    • 12.6.1. By Product Type
    • 12.6.2. By Disease Indication
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country

13. Middle East & Africa Hemophilia Treatment Drug Market Analysis and Forecast

  • 13.1.Introduction
    • 13.1.1. Key Findings
  • 13.2.Market Value Forecast By Product Type, 2014-2024
    • 13.2.1. Recombinant coagulation factor concentrates
      • 13.2.1.1. Factor VIII
      • 13.2.1.2. Factor IX
      • 13.2.1.3. Combination
    • 13.2.2. Plasma derived coagulation factor concentrates
      • 13.2.2.1. Factor VIII
      • 13.2.2.2. Factor IX
      • 13.2.2.3. Combination
    • 13.2.3. Desmopressin
    • 13.2.4. Antifibrinolytic agents
  • 13.3.Market Value Forecast By Disease Indication, 2014-2024
    • 13.3.1. Hemophilia A
    • 13.3.2. Hemophilia B
    • 13.3.3. Others
  • 13.4.Market Value Forecast By Distribution Channel, 2014-2024
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. E- commerce
  • 13.5.Market Value Forecast By Country, 2014-2024
    • 13.5.1. South Africa
    • 13.5.2. UAE
    • 13.5.3. Saudi Arabia
    • 13.5.4. Rest of Middle East and Africa
  • 13.6.Market Attractiveness Analysis
    • 13.6.1. By Product Type
    • 13.6.2. By Disease Indication
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country

14. Competition Landscape

  • 14.1.Market Player - Competition Matrix (By Tier and Size of companies)
  • 14.2.Market Share Analysis By Company (2015)
  • 14.3.Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
    • 14.3.1. Pfizer, Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Business Overview
      • 14.3.1.3 Financial Overview
      • 14.3.1.4 SWOT Analysis
      • 14.3.1.5 Strategic Overview
    • 14.3.2. Biotest AG
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Business Overview
      • 14.3.2.3 Financial Overview
      • 14.3.2.4 SWOT Analysis
      • 14.3.2.5 Strategic Overview
    • 14.3.3. CSL Behring
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Business Overview
      • 14.3.3.3 Financial Overview
      • 14.3.3.4 SWOT Analysis
      • 14.3.3.5 Strategic Overview
    • 14.3.4. Kedrion
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Business Overview
      • 14.3.4.3 Financial Overview
      • 14.3.4.4 SWOT Analysis
      • 14.3.4.5 Strategic Overview
    • 14.3.5. Octapharma AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Business Overview
      • 14.3.5.3 Financial Overview
      • 14.3.5.4 SWOT Analysis
      • 14.3.5.5 Strategic Overview
    • 14.3.6. Shire Plc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Business Overview
      • 14.3.6.3 Financial Overview
      • 14.3.6.4 SWOT Analysis
      • 14.3.6.5 Strategic Overview
    • 14.3.7. Novo Nordisk A/S
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Business Overview
      • 14.3.7.3 Financial Overview
      • 14.3.7.4 SWOT Analysis
      • 14.3.7.5 Strategic Overview
    • 14.3.8. Bayer AG
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Business Overview
      • 14.3.8.3 Financial Overview
      • 14.3.8.4 SWOT Analysis
      • 14.3.8.5 Strategic Overview
    • 14.3.9. F. Hoffmann-La Roche Ltd.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Business Overview
      • 14.3.9.3 Financial Overview
      • 14.3.9.4 SWOT Analysis
      • 14.3.9.5 Strategic Overview
    • 14.3.10. Biogen
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Business Overview
      • 14.3.10.3 Financial Overview
      • 14.3.10.4 SWOT Analysis
      • 14.3.10.5 Strategic Overview

List of Tables

  • Table 01: Global Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Product Type, 2016-2024
  • Table 02: Global Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Recombinant Coagulation Factor Concentrates, 2016-2024
  • Table 03: Global Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Plasma derived coagulation factor concentrates, 2016-2024
  • Table 04: Europe Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2016-2024
  • Table 05: Global Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014-2024
  • Table 06: Global Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Region, 2016-2024
  • Table 07: North America Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Product Type, 2016-2024
  • Table 08: North America Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Recombinant coagulation factor concentrates, 2016-2024
  • Table 09: North America Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Plasma derived coagulation factor concentrates, 2016-2024
  • Table 10: North America Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2016-2024
  • Table 11: North America Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2024
  • Table 12: North America Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Country, 2016-2024
  • Table 13: Europe Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Product Type, 2016-2024
  • Table 14: Europe Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Recombinant coagulation factor concentrate, 2016-2024
  • Table 15: Europe Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Plasma derived coagulation factor concentrates, 2016-2024
  • Table 16: Europe Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2016-2024
  • Table 17: Europe Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2024
  • Table 18: Europe Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Country, 2016-2024
  • Table 19: Asia Pacific Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Product Type, 2016-2024
  • Table 20: Asia Pacific Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Recombinant coagulation factor concentrate, 2016-2024
  • Table 21: Asia Pacific Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Plasma derived coagulation factor concentrates, 2016-2024
  • Table 22: Asia Pacific Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2016-2024
  • Table 23: Asia Pacific Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2024
  • Table 24: Asia Pacific Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Country, 2016-2024
  • Table 25: Latin America Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Product Type, 2016-2024
  • Table 26: Latin America Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Recombinant coagulation factor concentrate, 2016-2024
  • Table 27: Latin America Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Plasma derived coagulation factor concentrates, 2016-2024
  • Table 28: Latin America Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2016-2024
  • Table 29: Latin America Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2024
  • Table 30: Latin America Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Country, 2016-2024
  • Table 31: Middle East & Africa Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Product Type, 2016-2024
  • Table 32: Middle East & Africa Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Recombinant coagulation factor concentrate, 2016-2024
  • Table 33: Middle East & Africa Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Plasma derived coagulation factor concentrates, 2016-2024
  • Table 34: Middle East & Africa Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2016-2024
  • Table 35: Middle East & Africa Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2024
  • Table 36: Middle East & Africa Hemophilia Treatment Drugs Size (US$ Mn) Forecast, by Country, 2016-2024

List of Figures

  • Figure 01: Global Hemophilia Treatment Drugs Market Value Share Analysis, by Product Type, 2016 and 2024
  • Figure 02: Global Recombinant Coagulation Factor Concentrates Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2024
  • Figure 03: Global Plasma Derived Coagulation Factor Concentrates Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2024
  • Figure 04: Global Desmopressin Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2024
  • Figure 05: Global Antifibrinolytic Agents Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2024
  • Figure 06: Global Hemophilia Treatment Drugs Market Value Share Analysis, by Disease Indication, 2016 and 2024
  • Figure 07: Global Hemophilia A Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2024
  • Figure 08: Global Hemophilia B Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2024
  • Figure 09: Global Others Market Revenue (US$ Mn) and
  • Figure 10: Global Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024
  • Figure 11: Global Hospital Pharmacies Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2024
  • Figure 12: Global Retail Pharmacies Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2024
  • Figure 13: Global E-commerce Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2024
  • Figure 14: Global Hemophilia Treatment Drugs Market Value Share Analysis, by Region, 2016 and 2024
  • Figure 15: Hemophilia Treatment Drugs Market Attractiveness Analysis, by Region
  • Figure 16: North America Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2016-2024
  • Figure 17: North America Market Attractiveness Analysis, by Country
  • Figure 18: North America Market Value Share Analysis, by Product Type, 2016 and 2024
  • Figure 19: North America Market Value Share Analysis, by Disease Indication, 2016 and 2024
  • Figure 20: North America Market Value Share Analysis, by E Distribution Channel, 2016 and 2024
  • Figure 21: North America Market Value Share Analysis, by Country, 2016 and 2024
  • Figure 22: North America Market Attractiveness Analysis, by Product Type
  • Figure 23: North America Market Attractiveness Analysis, by Disease Indication
  • Figure 24: North America Market Attractiveness Analysis, by Distribution Channel
  • Figure 25: Europe Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 26: Europe Market Attractiveness Analysis, by Country
  • Figure 27: Europe Market Value Share Analysis, by Product Type, 2016 and 2024
  • Figure 28: Europe Market Value Share Analysis, by Disease Indication, 2016 and 2024
  • Figure 29: Europe Market Value Share Analysis, by Distribution Channel, 2016 and 2024
  • Figure 30: Europe Market Value Share Analysis, by Country, 2016 and 2024
  • Figure 31: Europe Market Attractiveness Analysis, by Product Type
  • Figure 32: Europe Market Attractiveness Analysis, by Disease Indication
  • Figure 33: Europe Market Attractiveness Analysis, by Distribution Channel
  • Figure 34: Asia Pacific Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 35: Asia Pacific Market Attractiveness Analysis, by Country
  • Figure 36: Asia Pacific Market Value Share Analysis, by Product Type, 2016 and 2024
  • Figure 37: Asia Pacific Market Value Share Analysis, by Disease Indication, 2016 and 2024
  • Figure 38: Asia Pacific Market Value Share Analysis, by Distribution Channel, 2016 and 2024
  • Figure 39: Asia Pacific Market Value Share Analysis, by Country, 2016 and 2024
  • Figure 40: Asia Pacific Market Attractiveness Analysis, by Product Type
  • Figure 41: Asia Pacific Market Attractiveness Analysis, by Disease Indication
  • Figure 42: Asia Pacific Market Attractiveness Analysis, by Distribution Channel
  • Figure 43: Latin America Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 44: Latin America Market Attractiveness Analysis, by Country
  • Figure 45: Latin America Market Value Share Analysis, by Product Type, 2016 and 2024
  • Figure 46: Latin America Market Value Share Analysis, by Disease Indication, 2016 and 2024
  • Figure 47: Latin America Market Value Share Analysis, by Distribution Channel, 2016 and 2024
  • Figure 48: Latin America Market Value Share Analysis, by Country, 2016 and 2024
  • Figure 49: Latin America Market Attractiveness Analysis, by Product
  • Figure 50: Latin America Market Attractiveness Analysis, by Disease Indication
  • Figure 51: Latin America Market Attractiveness Analysis, by Distribution Channel
  • Figure 52: Middle East & Africa Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 53: Middle East & Africa Market Attractiveness Analysis, by Country
  • Figure 54: Middle East & Africa Market Value Share Analysis, by Product Type, 2016 and 2024
  • Figure 55: Middle East & Africa Market Value Share Analysis, by Disease Indication, 2016 and 2024
  • Figure 56: Middle East & Africa Market Value Share Analysis, by Distribution Channel, 2016 and 2024
  • Figure 57: Middle East & Africa Market Value Share Analysis, by Country, 2016 and 2024
  • Figure 58: Middle East & Africa Market Attractiveness Analysis, by Product
  • Figure 59: Middle East & Africa Market Attractiveness Analysis, by Disease Indication
  • Figure 60: Middle East & Africa Market Attractiveness Analysis, by Distribution Channel
  • Figure 61: Global Hemophilia Treatment Drugs Market Share Analysis, by Company (2015)
Back to Top